Overall verdict
Neutral
6.1/10
1-year performance
+11.25%
Score breakdown
Up 11.3% over 1 year, 64% of the 52-week range.
Strongest: Valuation 8.6/10. Weakest: Growth 1.7/10.
25 analysts, target +0.2% vs the price.
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes.
The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations.
The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Robert Peat
Founded
1792
Employees
67 700
Revenue / employee
4.1M USD
Next earnings
February 4, 2027
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.59%
- FMR LLC2.59%
- Bank of New York Mellon Corp0.62%
- Rest of the register94.20%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
318.05 USD
52-week low
257.85 USD
1-year performance
11.25%
Rising
Year-to-date performance
7.17%
Rising
Drawdown
-6.78%
Mild pullback
Position in the 52-week range
64% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned more, but shaking 2.3 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| The Cigna Group | $81,293 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 2.3 times as much as the world ETF.
- Worst fall:-78 % between May 2007 and November 2008. $10,000 placed at the top fell to $2,171. The world ETF, at worst: -53 %. Back to its high in 50 months.
The Cigna Group earned more than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- The Cigna Group: $81,293
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 522.19 USD - 534.35 USD (2 methods agree)
The price implies growth of -4.94% per year; the company grows at -0.69%.
Gross margin 20.7%, net margin 2.1%, ROIC 8.3%, ROE 14.1%.
Net margin
2.09%
Low
Sector 4.74%|S&P 13.40%
Gross margin
20.69%
Low
Return on equity (ROE)
14.06%
High
Sector 10.36%|S&P 17.06%
Return on invested capital (ROIC)
8.26%
High
Free cash flow margin (FCF)
2.89%
Low
Profit-to-cash conversion (FCF conversion)
1.38x
High
Margin stability
1.4 pts
Very steady
Revenue to net income
Growth
1.7/10Revenue up 5.7% over 1 year, 11.4% a year over 5, EPS -0.7% a year over 5.
Revenue (trailing 12 months)
286Md USD
Revenue growth (1y)
5.65%
Moderate
Revenue growth (3y)
52.68%
Strong
EPS growth (1y)
-21.71%
Declining
EPS CAGR (5y)
-0.69%
Declining
EPS revisions (3 months)
0.36%
Revised up
Valuation
8.6/10P/E 13.1x, forward P/E 12.5x, EV/EBITDA 8.0x. The multiple sits in the 34th percentile of its own 5-year history.
P/E (TTM)
13.1x
Cheap
Sector 27.8x|S&P 23.6x
Forward P/E
12.5x
Cheap
EV / EBITDA
8.0x
Fair
Sector 12.5x|S&P 15.5x
PEG
—
Sector -0.20|S&P 0.91
Fair value (reverse DCF)
528.27 USD
Deeply undervalued
P/E vs its own 5-year history
among the 34% lowest valuations
Cheaper than usual
Market cap
78.1Md USD
Financial strength
6.0/10Cash covers 19.9% of the debt, net debt/EBITDA 1.8x.
Net debt / EBITDA
1.8x
Solid
Gearing (net debt / equity)
57.08%
Solid
Cash
6.2Md USD
Cash / market cap
7.92%
Tight
Cash / total debt
19.86%
Tight
Interest coverage
7.1x
Solid
Net debt
25.0Md USD
Equity
43.7Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 303.13 USD
- MM20300.43
- MM50286.69
- MM200282.42
- RSI 1457.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.83%
200-day average slope, 3 months
+1.25%
50-day average slope, 1 month
+3.32%
Price structure
flat
Bullish RSI divergence
No
20-day volatility
2.04 % per day
Volatility change
+19.22%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 23.76 (9) | 30.62 (21) | 288 350 (14) | 13 190 (14) | 6 184 (6) |
| 2027 | 27.24 (10) | 33.33 (23) | 299 898 (15) | 14 221 (14) | 6 981 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 3 | HNGE | 6.4 | 7.0 | 9.5Md USD | 61.3x | 20.7 % | 52.4 % | 44.7 % | -1.6x | 3.3 % | 171.5 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 78.1Md USD | 13.1x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.6 % | 11.3 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
